NSFQ-104(NSFQ-104) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用方式-

作用机制-

治疗领域

感染

在研适应症-

非在研适应症

细菌感染

原研机构

Wakunaga Pharmaceutical Co., Ltd.

Roussel Uclaf SA

在研机构-

非在研机构

Wakunaga Pharmaceutical Co., Ltd.

Roussel Uclaf SA

权益机构-

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 NSFQ-104 相关的临床结果

登录后查看更多信息

100 项与 NSFQ-104 相关的转化医学

登录后查看更多信息

100 项与 NSFQ-104 相关的专利（医药）

登录后查看更多信息

3

项与 NSFQ-104 相关的文献（医药）

1998-06-01·Antimicrobial Agents and Chemotherapy2区 · 医学

Mode of Action of Sulfanilyl Fluoroquinolones

2区 · 医学

Article

作者: Manzo, Ruben H. ; Nieto, Marcelo ; Mazzieri, Maria Rosa ; Then, Rudolf ; Alovero, Fabiana

ABSTRACT The mode of action of sulfanilyl fluoroquinolones (NSFQs) was investigated with NSFQ-104, NSFQ-105, and some structurally related compounds. Evidence arising from interactions with p -aminobenzoic acid and trimethoprim suggested that a sulfonamidelike mechanism of action makes little or no contribution to the in vitro activity of NSFQs. NSFQ-105 showed an activity that inhibits gyrase-catalyzed DNA supercoiling that is similar to the activity of other fluoroquinolones. Also, NSFQ-105 uptake was decreased by the presence of Mg 2+ and increased by a lower pH. These results indicate that NSFQs having only one ionizable group could exhibit more favorable kinetics of access to the bacterial cell than zwitterionic fluoroquinolones.

1995-07-01·Expert Opinion on Investigational Drugs

Monthly Update: Anti-infectives: New fluoroquinolones issued in 1994

作者: Bryskier, André

1994 was hardly a ‘Vintage year’ for new quinolones. The only new entities were two from Korea (CFC 222, DW 116), one from Medionalum-Italy (MF 5137), two from Argentina (NSFQ-104, 105), one from Japan Wakunaga (WQ 2128), and a series of 7-azetidinyl derivatives from Esteves Spain [1].

1994-01-01·Journal of Antimicrobial Chemotherapy2区 · 医学

In-vitro activity of new sulphanilil fluoroquinolones against Staphylococcus aureus

2区 · 医学

Article

作者: Ruben H. Manzo ; Fabiana L. Alovero ; Daniel A. Allemandi

Two new quinolones, NSFQ-104 and NSFQ-105, derivatives of ciprofloxacin and norfloxacin with a 4-(4-aminophenylsulphonyl)-1-piperazinyl at position 7 showed better in-vitro activity against strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus than ciprofloxacin or norfloxacin. Their in-vitro activity was enhanced at pH 5.5.

100 项与 NSFQ-104 相关的药物交易

登录后查看更多信息